Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Pia Burman

Physician

Default user image.

Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.

Author

  • Pia Burman
  • Britt Edén-Engström
  • Bertil Ekman
  • F Anders Karlsson
  • Erik Schwarcz
  • Jeanette Wahlberg

Summary, in English

The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD.

Department/s

  • Genomics, Diabetes and Endocrinology

Publishing year

2016

Language

English

Pages

17-24

Publication/Series

European Journal of Endocrinology

Volume

174

Issue

1

Document type

Journal article

Publisher

Society of the European Journal of Endocrinology

Topic

  • Endocrinology and Diabetes

Status

Published

Research group

  • Genomics, Diabetes and Endocrinology

ISBN/ISSN/Other

  • ISSN: 1479-683X